Please assess the completion status of the following clinical trial:

Trial Title: Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 years old~* English speaking~* Able to provide informed consent~* Scheduled to receive a corticosteroid burst of at least 20 mg prednisone or equivalent for at least 7 days~Exclusion Criteria:~* History of allergic reaction to memantine and/or riluzole~* Pregnant or nursing women~* History of liver disease, myocardial infarction, renal failure, diabetes with poor glycemic control, or other unstable medical condition~* Mental retardation, dementia, or other severe cognitive disorder~* Prior prednisone therapy in the last 14 days~* Current alcohol/substance abuse/dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Memantine (Type: ACTIVE_COMPARATOR): Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
- Placebo (Type: PLACEBO_COMPARATOR): Inactive ingredient matching the active medication in appearance
- Riluzole (Type: ACTIVE_COMPARATOR): Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).